

March 11-12, 2019  
Amsterdam, NetherlandsJ Clin Immunol Allergy 2019, Volume:5  
DOI: 10.21767/2471-304X-C1-009

# MIF PROTEINS AS PROTOTYPICAL INNATE CHEMOKINES IN INFLAMMATORY AND CARDIOVASCULAR DISEASE

**Jurgen Bernhagen**<sup>1, 2</sup><sup>1</sup>Ludwig-Maximilians University of Munich, Germany<sup>2</sup>University of London, UK

Inflammatory processes such as those promoting atherosclerotic lesion formations are pivotally driven by components of the innate and adaptive immune axis. Chemokines and their receptors are particularly prominent part of the innate immune arm. While the role of classical chemokines, i.e., belonging to the CC or CXC families is increasingly well understood, an emerging family of chemokine like inflammatory mediators termed innate chemokines, CLF chemokines or micro-chemokines, which additionally structurally and functionally overlaps with the mediator class of alarmins, has been identified, but it yet has to be comprehensively characterized regarding its molecular mechanism and role in disease. For example, innate chemokines modulate inflammatory reactions in the atherogenic arterial wall and numerous other inflamed tissues, but the precise receptor signaling mechanisms are still only poorly understood. What is known is that many innate chemokines share functional homology with classical chemokines and signal through classical chemokine receptors, whereas they do not exhibit conserved structural features such as N-terminal tandem cysteine residues or the chemokine fold. Thus, important receptor binding motifs yet have to be characterized. This lecture will give an overview of the mechanisms underlying molecular hijacking of classical chemokine receptors by innate chemokines, featuring their pathophysiological role. Examples will encompass high mobility group binding protein-1 (HMGB1), macrophage migration inhibitory factor (MIF), MIF-2/D-D (D dopachrome tautomerase) T and certain  $\beta$ -defensins. Receptor usage, binding domains, signalling, innate immune cell regulation and involvement in various inflammatory conditions, including atherosclerosis will be discussed. The lecture will outline strategies to target such mediators in disease either in conjunction or explicit exclusion of the co-targeting of classical chemokines. Finally, a cross kingdom analysis will be shared offering more general understanding of some of these mediators.

[juergen.bernhagen@med.uni-muenchen.de](mailto:juergen.bernhagen@med.uni-muenchen.de)